Health Quadruplet Shows ‘Excellent Activity’ in Myeloma Patients Who Defer HSCT Posted on April 29, 2024 by miyuru Oncology/Hematology > Myeloma — ORR reaches 90% with isatuximab plus KRd in freshly identified illness by Mike BassettStaff Writer, MedPage Today April 26, 2024 Including the CD38 monoclonal antibody isatuximab….